Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of IMVT-1402 in adults with Graves' disease
NL-OMON61108Phase 2Not yet recruiting
- Sponsor
- Immunovant, Inc.
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of IMVT-1402 in Graves' disease (3 arms), sponsored by Immunovant, Inc. Primary endpoint: Percentage of Group A participants who remain euthyroid, off antithyroid drugs, and off IMVT-1402. Planned start May 2026; status: not yet recruiting.
02
Drugs
IMVT-1402
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NL-OMON61108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61108.